EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

Crohn Disease Clinical Trial

— MAINTAIN  

Official title:

A Phase 1, Multicentre, 2-Part, Randomised, Parallel-arm, Placebo-controlled, Partially Double-blind Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission in Participants With Mild to Moderate Crohn's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05542355
• Other study ID #: EXL01-CD-001
• Secondary ID: 2021-003432-81
• Status: Recruiting
• Phase: Phase 1
• Start date: March 20, 2023
• Est. completion date: October 2025

Study information

• Verified date: November 2023
• Source: Exeliom Biosciences
• Contact: Benjamin Hadida
• Phone: +33 6 72 43 72 94
• Email: bhadida[@]exeliombio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 1, 2-part, multicentre study to evaluate the safety and preliminary efficacy of the oral administration of EXL01 in the maintenance of corticosteroid-induced clinical response/remission in participants with mild to moderate Crohn's Disease (CD).

Description:

Initially, all participants will received standard of care (SoC) corticosteroid induction therapy for 3 to 7 weeks. Participants who meet the protocol defined criteria for response after corticosteroid therapy will enter a Maintenance Period. Participants not in clinical response/remission at the end of the Induction Period will discontinue the study without further study treatment. In the Maintenance Period, participants will receive oral EXL01 or placebo in combination with corticosteroid treatment (that is progressively tapered) and be monitored for safety and efficacy.

The study will be conducted in 2 parts:

• Part A: Participants eligible for maintenance treatment will receive open-label oral EXL01 for up to 24 weeks.

• Part B: Participants eligible for maintenance treatment will be randomised 2:1 to receive double blind oral EXL01 or placebo for up to 24 weeks.

Participants will be monitored for 30 days after end-of-treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 67
• Est. completion date: October 2025
• Est. primary completion date: October 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Key Inclusion Criteria:

Must meet all of the following criteria at the start of the Induction Period:

• Male or female aged =18 years and <75 years at the time of providing informed consent.

• A diagnosis of CD with ileal involvement for at least 3 months prior to Screening.

• A CDAI score >180 and <350.

• Active mucosal inflammation.

Key Exclusion Criteria:

• Stricture with obstructive syndrome <3 months prior to Screening.

• Stenosis making endoscopic access to the terminal ileum difficult.

• Received treatment with high dose corticosteroid (=40 mg prednisone daily) for >5 weeks within 3 months prior to Screening.

• Received =2 prior biologic treatments for CD including infliximab, ustekinumab, vedolizumab, adalimumab, and certolizumab.

• Major surgery or significant trauma =4 weeks prior to Screening.

• Small bowel resection >1 m in total or clinical manifestations of short bowel syndrome.

• Current stoma (ileostomy or a colostomy) or had a stoma in the last 6 months or any other intraabdominal surgery within 3 months prior to Screening.

• Started or stopped immunosuppressive therapy (thiopurine, methotrexate, tacrolimus, or other classical immunosuppressant) within 3 months prior to Screening.

• Received faecal microbial transplant within 3 months prior to Screening.

• Systemic infection or other serious infection requiring systemic treatment within 30 days prior to Screening.

• Pregnant, breastfeeding, or expecting to conceive during the study.

Related Conditions & MeSH terms

• Crohn Disease

Intervention

Drug:
• EXL01
Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
• Placebo
Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).

Other:
• SoC corticosteroid - Induction Period
Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator
• SoC corticosteroid - Tapering
Same product as the Induction Period. Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop. OR Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop.

Locations

Country	Name	City	State
Belgium	Imelda Ziekenhuis Bonheiden	Antwerp
Belgium	CHU de Liege	Liège
Poland	Zespól Poradni Specjalistycznych REUMED	Lublin
Poland	Centrum Medyczne "Medyk" Sp. zo.o. Sp.K	Rzeszów
Poland	Endoskopia Sp. z o. o., Ul. B.Chrobrego 6/8	Sopot
Poland	Centrum Zdrowia MDM	Warszawa
Poland	Niepubliczny Zaklad Opieki Zdrowotnej	Warszawa

Sponsors (2)

Lead Sponsor	Collaborator
Exeliom Biosciences	Alimentiv Inc.

Countries where clinical trial is conducted

Belgium,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The systemic and intestinal safety and tolerability of orally administered EXL01	Number of participants with adverse events (AE[s]). Number of participants with treatment discontinuations due to an AE. AEs assessed by CTCAE v5.0	Up to 43 weeks
Secondary	Proportion of participants in steroid-free clinical remission at Week 24	Endpoints: Crohn's disease activity index (CDAI) score (higher scores indicate more active/severe disease) and use of corticosteroids	Maintenance Period Week 24
Secondary	Proportion of participants in steroid-free clinical remission and mucosal healing at Week 24	This is a composite measure. Endpoints: CDAI score, simple endoscopic score for Crohn's Disease (SES-CD; higher scores indicate more severe disease), and use of corticosteroids	Maintenance Period Week 24
Secondary	Proportion of participants in steroid free clinical remission and mucosal healing and normal inflammatory markers at Week 24	This is a composite measure. Endpoints: CDAI score, SES-CD score, C-reactive protein (CRP) level (a marker of inflammation), faecal calprotectin level (a marker of intestinal inflammation), and use of corticosteroids	Maintenance Period Week 24
Secondary	Proportion of participants with an endoscopic response at Week 24	Endpoint: SES-CD score	Maintenance Period Week 24
Secondary	Time to clinical relapse in participants with CD treated with EXL01 to participants treated with placebo (Part B only)	Time to clinical relapse, defined as the time from first dose of EXL01 or placebo to first documented clinical relapse (Part B only)	Maintenance Period Baseline to Week 24
Secondary	Comparison of the SES-CD and histology of the intestinal mucosa in participants with CD treated with EXL01 to participants treated with placebo (Part B only)	This is a composite measure. Endpoints: SES-CD score, Robarts Histopathology Index score (measures histological disease activity; higher scores indicate more severe disease activity)	Maintenance Period Baseline to Week 24
Secondary	Comparison of the evolution of the faecal and mucosa-associated microbiota in participants with CD treated with EXL01 to participants treated with placebo (Part B only)	This is a composite measure. 16S sequencing / shotgun metagenomics and specific quantitative polymerase chain reaction (qPCR)/digital droplet (dd)PCR	Maintenance Period Baseline to Week 24